Total Payments
$935,398
2024 Payments
$50,038
Companies
9
Transactions
342
Medicare Patients
49
Medicare Billing
$5,804
Payment Breakdown by Category
Consulting$882,355 (94.3%)
Research$39,850 (4.3%)
Travel$10,805 (1.2%)
Food & Beverage$2,128 (0.2%)
Other$259.93 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $882,355 | 286 | 94.3% |
| Unspecified | $39,850 | 21 | 4.3% |
| Travel and Lodging | $10,805 | 22 | 1.2% |
| Food and Beverage | $2,128 | 12 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $259.93 | 1 | 0.0% |
Payments by Type
General
$895,548
321 transactions
Research
$39,850
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $278,568 | 125 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $277,345 | 86 | $0 (2024) |
| PFIZER INC. | $157,657 | 40 | $0 (2023) |
| GlaxoSmithKline, LLC. | $124,439 | 42 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $64,424 | 19 | $0 (2017) |
| Alexion Pharmaceuticals, Inc. | $16,539 | 21 | $0 (2023) |
| Takeda Development Center Americas, Inc. | $16,225 | 7 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $124.65 | 1 | $0 (2017) |
| Cook Medical LLC | $77.31 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $50,038 | 16 | GlaxoSmithKline, LLC. ($20,488) |
| 2023 | $85,138 | 30 | GlaxoSmithKline, LLC. ($30,663) |
| 2022 | $77,339 | 36 | Takeda Pharmaceuticals U.S.A., Inc. ($34,064) |
| 2021 | $113,804 | 48 | Takeda Pharmaceuticals U.S.A., Inc. ($50,601) |
| 2020 | $123,380 | 44 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($52,818) |
| 2019 | $163,798 | 51 | Takeda Pharmaceuticals U.S.A., Inc. ($59,538) |
| 2018 | $128,551 | 53 | Takeda Pharmaceuticals U.S.A., Inc. ($50,780) |
| 2017 | $193,351 | 64 | Millennium Pharmaceuticals, Inc. ($64,424) |
All Payment Transactions
342 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $10,037.50 | General |
| 12/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: NEPHROLOGY | ||||||
| 11/15/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: NEPHROLOGY | ||||||
| 10/11/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| Category: NEPHROLOGY | ||||||
| 09/13/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: NEPHROLOGY | ||||||
| 08/14/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: NEPHROLOGY | ||||||
| 07/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: NEPHROLOGY | ||||||
| 06/13/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: NEPHROLOGY | ||||||
| 05/16/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $10,450.00 | General |
| 05/14/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: NEPHROLOGY | ||||||
| 05/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $6,300.00 | General |
| 04/12/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: NEPHROLOGY | ||||||
| 03/14/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: NEPHROLOGY | ||||||
| 02/14/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| Category: NEPHROLOGY | ||||||
| 01/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 01/10/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: NEPHROLOGY | ||||||
| 12/14/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| Category: NEPHROLOGY | ||||||
| 11/14/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: NEPHROLOGY | ||||||
| 10/12/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: NEPHROLOGY | ||||||
| 10/04/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $8,100.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | ||||||
| 09/26/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $6,325.00 | General |
| 09/12/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: NEPHROLOGY | ||||||
| 08/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $5,550.00 | Research |
| Study: A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatiti s With Fibrosis Stages 2 Through 4 | ||||||
| 08/11/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: NEPHROLOGY | ||||||
| 08/11/2023 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $566.64 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | Takeda Pharmaceuticals U.S.A., Inc. | $8,100 | 1 |
| A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatiti s With Fibrosis Stages 2 Through 4 | Takeda Pharmaceuticals U.S.A., Inc. | $5,550 | 1 |
| HEPATIC IMPAIRMENT | Takeda Pharmaceuticals U.S.A., Inc. | $4,950 | 1 |
| Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months | Alexion Pharmaceuticals, Inc. | $3,825 | 1 |
| EU DIGITAL MEDICINE EXPLORATORY STUDY IN PATIENTS WITH SCHIZOPHRENIA TO ASSESS PATIENT EXPERIENCE AND SATISFACTION | Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,200 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-PART PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAK-951 IN HEALTHY SUBJECTS | Takeda Pharmaceuticals U.S.A., Inc. | $1,925 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of OPC-34172 in the Treatment of Adolescent Patients with Schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,800 | 1 |
| A Phase 2, Multicenter, Randomized, Double-blind, Active- and Placebo-controlled Trial of the Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,700 | 1 |
| A Phase 1, Open-label, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Single Doses of Aripiprazole Intramuscular Depot Administered Gluteally in Adult Subjects with Schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,200 | 1 |
| A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects with Bipolar I Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | $800.00 | 1 |
| A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Tablet Doses of OPC-167832 and the Effect of Food in Healthy Subjects | Otsuka Pharmaceutical Development & Commercialization, Inc. | $800.00 | 1 |
| A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to < 13 Years old) With Central Nervous System Disorders | Otsuka Pharmaceutical Development & Commercialization, Inc. | $800.00 | 1 |
| A Single-center, Double-blind, Randomized, Placebo- and Active-controlled, Three period Crossover Thorough QT Study Evaluating the Effect of Centanafadine Exposures on Cardiac Repolarizaton in Healthy Male and Female Subjects | Otsuka Pharmaceutical Development & Commercialization, Inc. | $800.00 | 1 |
| An Open-label, Parallel-arm Trial to Assess the Potential for Cytochrome P450 CYP2D6 and CYP1A2 Pharmacokinetic Interactions with Centanafadine in Healthy Subjects | Otsuka Pharmaceutical Development & Commercialization, Inc. | $800.00 | 1 |
| PHASE 1 TRIAL TO ASSESS THE MASS BALANCE AND PHARMACOKINETICS OF A SINGLE ORAL ADMINISTRATION OF 14C-CENTANAFADINE IN HEALTHY SUBJECTS | Otsuka Pharmaceutical Development & Commercialization, Inc. | $800.00 | 1 |
| Protocol 331-201-00080: A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated with Bipolar I Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | $800.00 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. | Otsuka Pharmaceutical Development & Commercialization, Inc. | $600.00 | 1 |
| AN OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER, PILOT TRIAL TO ASSESS THE BIOEQUIVALENCE OF ORAL DOSES OF DM-R NO IEMVERSUS RISPERDAL TABLETS IN HEALTHY SUBJESCT. | Otsuka Pharmaceutical Development & Commercialization, Inc. | $600.00 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $400.00 | 1 |
| AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $400.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 12 | 12 | $5,364 | $1,150 |
| 2021 | 2 | 37 | 37 | $18,749 | $4,654 |
Total Patients
49
Total Services
49
Medicare Billing
$5,804
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $5,364 | $1,150 | 21.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 24 | 24 | $10,728 | $2,568 | 23.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $8,021 | $2,086 | 26.0% |
About Dr. David Alpers, MD
Dr. David Alpers, MD is a Gastroenterology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740207208.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Alpers, MD has received a total of $935,398 in payments from pharmaceutical and medical device companies, with $50,038 received in 2024. These payments were reported across 342 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($882,355).
As a Medicare-enrolled provider, Alpers has provided services to 49 Medicare beneficiaries, totaling 49 services with total Medicare billing of $5,804. Data is available for 2 years (2021–2022), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Saint Louis, MO
- Active Since 07/17/2006
- Last Updated 11/15/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1740207208
Products in Payments
- TOLVAPTAN (Drug) $137,582
- SAMSCA (Drug) $108,568
- ENTYVIO (Biological) $46,888
- JYNARQUE (Drug) $16,918
- Entyvio (Biological) $8,800
- REXULTI (Drug) $4,800
- ABILIFY MAINTENA (Drug) $4,400
- TAKHZYRO (Biological) $1,200
- JANUVIA (Drug) $124.65
- COOK MEDICAL HEMOSPRAY (Device) $77.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Saint Louis
Dr. Gregory Sayuk, Md, MD
Gastroenterology — Payments: $1.2M
Gastroenterology $1.2M
Dr. Matthew Ciorba, Md, MD
Gastroenterology — Payments: $483,512
Gastroenterology $483,512
Dr. Jeffrey Crippin, Md, MD
Gastroenterology — Payments: $413,620
Gastroenterology $413,620
Dr. Mauricio Lisker Melman, Md, MD
Gastroenterology — Payments: $325,080
Gastroenterology $325,080
Dr. Adrian Di Bisceglie, M.d, M.D
Gastroenterology — Payments: $143,272
Gastroenterology $143,272
Dr. Rajesh Keswani, Md, MD
Gastroenterology — Payments: $132,086
Gastroenterology $132,086